A new hope: Novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53

British Journal of Haematology

Volumn 167, Issue 2, 2014, Pages 149-161

  Shindiapina, Polina ^a   Brown, Jennifer R ^b   Danilov, Alexey V ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

B cell receptor; Chronic lymphocytic leukaemia; TP53

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; BREAKPOINT CLUSTER REGION PROTEIN; CYCLOPHOSPHAMIDE; DINACICLIB; FLUDARABINE; IBRUTINIB; IDELALISIB; LENALIDOMIDE; OBINUTUZUMAB; OFATUMUMAB; PROTEIN P53; RITUXIMAB; STEROID; ANTINEOPLASTIC AGENT; TP53 PROTEIN, HUMAN;

APOPTOSIS; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG RESPONSE; GENE DELETION; GENE DISRUPTION; GENE FREQUENCY; GENE MUTATION; HUMAN; LEUKEMIA CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TP53 GENE; CHROMOSOME 17; CHROMOSOME DELETION; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; GENES, P53; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR TARGETED THERAPY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84908556992     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13042     Document Type: Review

References (122)

1. Badoux, X.C., Keating, M.J., Wang, X., O'Brien, S.M., Ferrajoli, A., Faderl, S., Burger, J., Koller, C., Lerner, S., Kantarjian, H. & Wierda, W.G. (2011) Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood, 118, 2085-2093.
2. Badoux, X.C., Keating, M.J., Wen, S.J., Wierda, W.G., O'Brien, S.M., Faderl, S., Sargent, R., Burger, J.A. & Ferrajoli, A. (2013) Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 31, 584-591.
3. Barrientos, J.C., Furman, R.R., Leonard, J., Flinn, I., Rai, K.R., De Vos, S., Schreeder, M.T., Wagner-Johnston, N.D., Sharman, J.P., Boyd, T.E., Fowler, N.H., Holes, L., Johnson, D.M., Li, D., Dansey, R.D., Jahn, T.M. & Coutre, S.E. (2013) Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL. In: 2013 ASCO Annual Meeting, Vol. 31. Journal of Clinical Oncology, Chicago, IL, Abstract 7017.
4. Bosch, F., Abrisqueta, P., Villamor, N., Terol, M.J., Gonzalez-Barca, E., Ferra, C., Gonzalez Diaz, M., Abella, E., Delgado, J., Carbonell, F., Garcia Marco, J.A., Escoda, L., Ferrer, S., Monzo, E., Gonzalez, Y., Estany, C., Jarque, I., Salamero, O., Muntanola, A. & Montserrat, E. (2009) Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. Journal of Clinical Oncology, 27, 4578-4584.
5. Bowen, D.A., Call, T.G., Jenkins, G.D., Zent, C.S., Schwager, S.M., Van Dyke, D.L., Jelinek, D.F., Kay, N.E. & Shanafelt, T.D. (2007) Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leukaemia & Lymphoma, 48, 2412-2417.
6. Brenner, H., Gondos, A. & Pulte, D. (2008) Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood, 111, 4916-4921.
7. Brown, J.R., Furman, R.R., Flinn, I., Coutre, S.E., Wagner-Johnston, N.D., Kahl, B.S., Spurgeon, S.E., Benson, D.M., Peterman, S., Johnson, D.M., Li, D., Dansey, R.D., Jahn, T.M. & Byrd, J.C. (2013a) Final results of a phase I study of idelalisib (GS-1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL. Journal of Clinical Oncology (ASCO Annual Meeting Abstracts), 31, Abstract 7003.
8. Brown, J.R., Harb, W.A., Hill, B.T., Gabrilove, J., Sharman, J.P., Schreeder, M.T., Barr, P.M., Foran, J.M., Miller, T.P., Burger, J.A., Kelly, K.R., Mahadevan, D., Ma, S., Barnett, E., Marine, J., Nava-Parada, P., Azaryan, A., Mei, J. & Kipps, T.J. (2013b) Phase 1 study of single agent CC-292, a highly selective Bruton's Tyrosine Kinase (BTK) inhibitor, in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). In: American Society of Hematology Annual Meeting, Vol 122. Blood, New Orleans, LO, Abstract 1630.
9. Burger, J.A., Ghia, P., Rosenwald, A. & Caligaris-Cappio, F. (2009) The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood, 114, 3367-3375.
10. Byrd, J.C., Lin, T.S., Dalton, J.T., Wu, D., Phelps, M.A., Fischer, B., Moran, M., Blum, K.A., Rovin, B., Brooker-McEldowney, M., Broering, S., Schaaf, L.J., Johnson, A.J., Lucas, D.M., Heerema, N.A., Lozanski, G., Young, D.C., Suarez, J.R., Colevas, A.D. & Grever, M.R. (2007) Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood, 109, 399-404.
11. Byrd, J.C., Furman, R.R., Coutre, S.E., Flinn, I.W., Burger, J.A., Blum, K.A., Grant, B., Sharman, J.P., Coleman, M., Wierda, W.G., Jones, J.A., Zhao, W., Heerema, N.A., Johnson, A.J., Sukbuntherng, J., Chang, B.Y., Clow, F., Hedrick, E., Buggy, J.J., James, D.F. & O'Brien, S. (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 369, 32-42.
12. Byrd, J.C., Brown, J.R., O'Brien, S., Barrientos, J.C., Kay, N.E., Reddy, N.M., Coutre, S., Tam, C.S., Mulligan, S.P., Jaeger, U., Devereux, S., Barr, P.M., Furman, R.R., Kipps, T.J., Cymbalista, F., Pocock, C., Thornton, P., Caligaris-Cappio, F., Robak, T., Delgado, J., Schuster, S.J., Montillo, M., Schuh, A., de Vos, S., Gill, D., Bloor, A., Dearden, C., Moreno, C., Jones, J.J., Chu, A.D., Fardis, M., McGreivy, J., Clow, F., James, D.F. & Hillmen, P. (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. New England Journal of Medicine, doi 10.1056/NEJMoa1400376.
13. Caligaris-Cappio, F. (1996) B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood, 87, 2615-2620.
14. Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M.J., Bezares, R.F., Pettitt, A.R., Hamblin, T., Milligan, D.W., Child, J.A., Hamilton, M.S., Dearden, C.E., Smith, A.G., Bosanquet, A.G., Davis, Z., Brito-Babapulle, V., Else, M., Wade, R. & Hillmen, P. (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet, 370, 230-239.
15. Chen, R., Keating, M.J., Gandhi, V. & Plunkett, W. (2005) Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood, 106, 2513-2519.
16. Cimmino, A., Calin, G.A., Fabbri, M., Iorio, M.V., Ferracin, M., Shimizu, M., Wojcik, S.E., Aqeilan, R.I., Zupo, S., Dono, M., Rassenti, L., Alder, H., Volinia, S., Liu, C.G., Kipps, T.J., Negrini, M. & Croce, C.M. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America, 102, 13944-13949.
17. Contri, A., Brunati, A.M., Trentin, L., Cabrelle, A., Miorin, M., Cesaro, L., Pinna, L.A., Zambello, R., Semenzato, G. & Donella-Deana, A. (2005) Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. The Journal of Clinical Investigation, 115, 369-378.
18. Corney, D.C., Flesken-Nikitin, A., Godwin, A.K., Wang, W. & Nikitin, A.Y. (2007) MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Research, 67, 8433-8438.
19. Coutre, S.E., Leonard, J.P., Barrientos, J.C., Vos, S.D., Flinn, I., Furman, R.R., Brown, J.R., Wagner-Johnston, N., Benson D.M. Jr, Schreeder, M.T., Sharman, J.P., Boyd, T., Spurgeon, S.E., Zelenetz, A.D., Lamanna, N., Kipps, T.J., Kahl, B.S., Bello, C.M., Burger, J.A., Rai, K.R., Dansey, R., Kim, Y., Holes, L.M., Lazarov, M., Dubowy, R.L. & O'Brien, S.M. (2013) Clinical activity Of idelalisib (GS-1101), a selective inhibitor Of PI3Kδ, in phase 1 and 2 trials in chronic lymphocytic leukemia (CLL): effect of Del(17p)/TP53 mutation, Del(11q), IGHV mutation, and NOTCH1 mutation. Blood (ASH Annual Meeting Abstracts), 122, 1632.
20. Damle, R.N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S.L., Buchbinder, A., Budman, D., Dittmar, K., Kolitz, J., Lichtman, S.M., Schulman, P., Vinciguerra, V.P., Rai, K.R., Ferrarini, M. & Chiorazzi, N. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood, 94, 1840-1847.
21. Danilov, A.V., Danilova, O.V., Klein, A.K. & Huber, B.T. (2006) Molecular pathogenesis of chronic lymphocytic leukemia. Current Molecular Medicine, 6, 665-675.
22. Danilov, A.V., Neupane, D., Nagaraja, A.S., Feofanova, E.V., Humphries, L.A., DiRenzo, J. & Korc, M. (2011) DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance. PLoS ONE, 6, e26815.
23. Danilov, A.V., Soderquist, R.S., Bates, D.J. & Eastman, A. (2013) Toward a cure for chronic lymphocytic leukemia: an attack on multiple fronts. Expert Review of Anticancer Therapy, 13, 1009-1012.
24. Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J. & Stilgenbauer, S. (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood, 85, 1580-1589.
25. Dohner, H., Stilgenbauer, S., James, M.R., Benner, A., Weilguni, T., Bentz, M., Fischer, K., Hunstein, W. & Lichter, P. (1997) 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood, 89, 2516-2522.
26. Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., Dohner, K., Bentz, M. & Lichter, P. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. New England Journal of Medicine, 343, 1910-1916.
27. Doubek, M., Brychtova, Y., Panovska, A., Trizuljak, J., Sebejova, L., Stehlikova, O., Chovancova, J., Malcikova, J., Smardova, J., Plevova, K., Volfova, P., Trbusek, M., Mraz, M., Majercakova, D., Obrtlikova, P., Karban, J., Smolej, L., Lindtnerova, A., Oltova, A., Jelinkova, E., Pospisilova, S. & Mayer, J. (2013) Ofatumumab added to dexamethasone in patients with relapsed or Refractory Chronic Lymphocytic Leukemia. Results from a phase II study of the czech leukemia study group for life. In: American Society of Hematology Annual Meeting, Vol. 122, p. 2877. Blood, New Orleans, LA.
28. Eichhorst, B.F., Busch, R., Stilgenbauer, S., Stauch, M., Bergmann, M.A., Ritgen, M., Kranzhofer, N., Rohrberg, R., Soling, U., Burkhard, O., Westermann, A., Goede, V., Schweighofer, C.D., Fischer, K., Fink, A.M., Wendtner, C.M., Brittinger, G., Dohner, H., Emmerich, B., Hallek, M. & GCLLSG (2009) First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood, 114, 3382-3391.
29. Elrouby, S., Thomas, A., Costin, D., Rosenberg, C.R., Potmesil, M., Silber, R. & Newcomb, E.W. (1993) P53 Gene mutation in B-cell chronic lymphocytic-leukemia is associated with drug-resistance and is independent of Mdr1/Mdr3 gene-expression. Blood, 82, 3452-3459.
30. Fabbri, M., Bottoni, A., Shimizu, M., Spizzo, R., Nicoloso, M.S., Rossi, S., Barbarotto, E., Cimmino, A., Adair, B., Wojcik, S.E., Valeri, N., Calore, F., Sampath, D., Fanini, F., Vannini, I., Musuraca, G., Dell'Aquila, M., Alder, H., Davuluri, R.V., Rassenti, L.Z., Negrini, M., Nakamura, T., Amadori, D., Kay, N.E., Rai, K.R., Keating, M.J., Kipps, T.J., Calin, G.A. & Croce, C.M. (2011) Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA, 305, 59-67.
31. Farooqui, M., Aue, G., Valdez, J., Martyr, S., Jones, J.A., Soto, S., Stetler-Stevenson, M., Yuan, C., Arthur, D.C., Thomas, F., Tian, X., Liu, D., Maric, I. & Wiestner, A. (2013) Single agent ibrutinib (PCI-32765) achieves equally good and durable responses in chronic lymphocytic leukemia (CLL) patients with and without deletion 17p. Blood (ASH Annual Meeting Abstracts), 122, 673.
32. Ferrajoli, A., Lee, B.N., Schlette, E.J., O'Brien, S.M., Gao, H., Wen, S.J., Wierda, W.G., Estrov, Z., Faderl, S., Cohen, E.N., Li, C.P., Reuben, J.M. & Keating, M.J. (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood, 111, 5291-5297.
33. Fischer, K., Cramer, P., Busch, R., Stilgenbauer, S., Bahlo, J., Schweighofer, C.D., Bottcher, S., Staib, P., Kiehl, M., Eckart, M.J., Kranz, G., Goede, V., Elter, T., Buhler, A., Winkler, D., Kneba, M., Dohner, H., Eichhorst, B.F., Hallek, M. & Wendtner, C.M. (2011) Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group. Journal of Clinical Oncology, 29, 3559-3566.
34. Fischer, K., Cramer, P., Busch, R., Bottcher, S., Bahlo, J., Schubert, J., Pfluger, K.H., Schott, S., Goede, V., Isfort, S., von Tresckow, J., Fink, A.M., Buhler, A., Winkler, D., Kreuzer, K.A., Staib, P., Ritgen, M., Kneba, M., Dohner, H., Eichhorst, B.F., Hallek, M., Stilgenbauer, S. & Wendtner, C.M. (2012) Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology, 30, 3209-3216.
35. Flinn, I.W., Neuberg, D.S., Grever, M.R., Dewald, G.W., Bennett, J.M., Paietta, E.M., Hussein, M.A., Appelbaum, F.R., Larson, R.A., Moore, D.F. Jr & Tallman, M.S. (2007) Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. Journal of Clinical Oncology, 25, 793-798.
36. Flinn, I., Patel, M., Kahl, B.S., Horwitz, S.M., Foss, F.M., Oki, Y., Porcu, P., Sweeney, J., Allen, K., Faia, K., Harris, P., Dunbar, J., Stern, H.M., Kelly, P. & O'Brien, S.M. (2013) Preliminary safety and efficacy Of IPI-145, a potent inhibitor of phosphoinositide-3-inase-δ, γ, in patients with chronic lymphocytic leukemia. In: American Society of Hematology Annual Meeting, Vol 122, pp. 677. Blood, New Orleans, LA.
37. Flores, E.R., Tsai, K.Y., Crowley, D., Sengupta, S., Yang, A., McKeon, F. & Jacks, T. (2002) p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature, 416, 560-564.
38. Flynn, J., Andritsos, L.A., Jones, J.A., Johnson, A.J., Maddocks, K., Wiley, E., Small, K., Im, E.K., Grever, M.R., Bannerji, R., Byrd, J.C. & Zhou, H. (2013) Dinaciclib (SCH 727965) is a Novel Cyclin-Dependent Kinase (CDK) inhibitor that exhibits activity in patients with Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL). In: American Society of Hematology Annual Meeting, Vol. 122, p. 871. Blood, New Orleans, LA.
39. Fukushima, N., Satoh, T., Sueoka, N., Sato, A., Ide, M., Hisatomi, T., Kuwahara, N., Tomimasu, R., Tsuneyoshi, N., Funai, N., Sano, M., Tokunaga, O. & Sueoka, E. (2006) Clinico-pathological characteristics of p63 expression in B-cell lymphoma. Cancer Science, 97, 1050-1055.
40. Furman, R.R., Sharman, J.P., Coutre, S.E., Cheson, B.D., Pagel, J.M., Hillmen, P., Barrientos, J.C., Zelenetz, A.D., Kipps, T.J., Flinn, I., Ghia, P., Eradat, H., Ervin, T., Lamanna, N., Coiffier, B., Pettitt, A.R., Ma, S., Stilgenbauer, S., Cramer, P., Aiello, M., Johnson, D.M., Miller, L.L., Li, D., Jahn, T.M., Dansey, R.D., Hallek, M. & O'Brien, S.M. (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 370, 997-1007.
41. Garg, R., Wierda, W., Ferrajoli, A., Abruzzo, L., Pierce, S., Lerner, S., Keating, M. & O'Brien, S. (2012) The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia. Cancer, 118, 3531-3537.
42. Geisler, C.H., van T'veer, M.B., Jurlander, J., Walewski, J., Tjonnfjord, G., Remes, M.I., Kimby, E., Kozak, T., Polliack, A., Wu, K.L., Wittebol, S., Abrahamse-Testroote, M.C., Doorduijn, J., Ghidey Alemayehu, W. & van Oers, M.H. (2014) Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk chronic lymphocytic leukemia: a randomized trial. Blood, 123, 3255-3262.
43. Gobessi, S., Laurenti, L., Longo, P.G., Carsetti, L., Berno, V., Sica, S., Leone, G. & Efremov, D.G. (2009) Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia, 23, 686-697.
44. Godbersen, J.C., Humphries, L.A., Danilova, O.V., Kebbekus, P.E., Brown, J.R., Eastman, A. & Danilov, A.V. (2014) The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-kappaB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clinical Cancer Research, 20, 1576-1589.
45. Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C.M., Chagorova, T., de la Serna, J., Dilhuydy, M.S., Illmer, T., Opat, S., Owen, C.J., Samoylova, O., Kreuzer, K.A., Stilgenbauer, S., Dohner, H., Langerak, A.W., Ritgen, M., Kneba, M., Asikanius, E., Humphrey, K., Wenger, M. & Hallek, M. (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. New England Journal of Medicine, 370, 1101-1110.
46. Gonzalez, D., Martinez, P., Wade, R., Hockley, S., Oscier, D., Matutes, E., Dearden, C.E., Richards, S.M., Catovsky, D. & Morgan, G.J. (2011) Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. Journal of Clinical Oncology, 29, 2223-2229.
47. Grever, M.R., Lucas, D.M., Dewald, G.W., Neuberg, D.S., Reed, J.C., Kitada, S., Flinn, I.W., Tallman, M.S., Appelbaum, F.R., Larson, R.A., Paietta, E., Jelinek, D.F., Gribben, J.G. & Byrd, J.C. (2007) Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. Journal of Clinical Oncology, 25, 799-804.
48. Hallek, M. (2013) Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. American Journal of Hematology, 88, 803-816.
49. Hallek, M., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Gruenhagen, U., Bergmann, M.A., Catalano, J., Zinzano, P.L., Cappio, F.C., Seymour, J.F., Berrebi, A., Jaeger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, A.B., Staib, P., Boettcher, S., Ritgen, M., Mendila, M., Kneba, M., Doehner, H., Stilgenbauer, S. & Fischer, K. (2009) First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study group. Blood (ASH Annual Meeting Abstracts), 114, 535.
50. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grunhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J.F., Berrebi, A., Jager, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Buhler, A., Winkler, D., Zenz, T., Bottcher, S., Ritgen, M., Mendila, M., Kneba, M., Dohner, H. & Stilgenbauer, S. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376, 1164-1174.
51. Hamblin, T.J., Davis, Z., Gardiner, A., Oscier, D.G. & Stevenson, F.K. (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood, 94, 1848-1854.
52. Herishanu, Y., Perez-Galan, P., Liu, D., Biancotto, A., Pittaluga, S., Vire, B., Gibellini, F., Njuguna, N., Lee, E., Stennett, L., Raghavachari, N., Liu, P., McCoy, J.P., Raffeld, M., Stetler-Stevenson, M., Yuan, C., Sherry, R., Arthur, D.C., Maric, I., White, T., Marti, G.E., Munson, P., Wilson, W.H. & Wiestner, A. (2011) The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood, 117, 563-574.
53. Hoellenriegel, J., Hartmann, E., Rosenwald, A., O'Brien, S., Keating, M., Wierda, W.G., Buggy, J.J. & Burger, J.A. (2013) Longitudinal gene expression profiling reveals down-regulation of BCR signaling-related genes in chronic lymphocytic leukemia (CLL) patients treated with ibrutinib plus rituximab. Blood (ASH Annual Meeting Abstracts), 122, 1631.
54. Howlader, N., Noone, A.M., Krapcho, M., Garshell, J., Neyman, N., Altekruse, S.F., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., Cho, H., Mariotto, A., Lewis, D.R., Chen, H.S., Feuer, E.J. & Cronin, K.A. (2013) SEER Cancer Statistics Review, 1975-2010. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
55. Hu, H., Xia, S.H., Li, A.D., Xu, X., Cai, Y., Han, Y.L., Wei, F., Chen, B.S., Huang, X.P., Han, Y.S., Zhang, J.W., Zhang, X., Wu, M. & Wang, M.R. (2002) Elevated expression of p63 protein in human esophageal squamous cell carcinomas. International Journal of Cancer, 102, 580-583.
56. Humphries, L.A., Godbersen, J.C., Danilova, O.V., Kaur, P., Christensen, B.C. & Danilov, A.V. (2013) Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia. British Journal of Haematology, 163, 590-602.
57. Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y. & Handa, H. (2010) Identification of a primary target of thalidomide teratogenicity. Science, 327, 1345-1350.
58. Johnson, S., Smith, A.G., Loffler, H., Osby, E., Juliusson, G., Emmerich, B., Wyld, P.J. & Hiddemann, W. (1996) Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet, 347, 1432-1438.
59. Jones, J.A., Ruppert, A.S., Zhao, W., Lin, T.S., Rai, K., Peterson, B., Larson, R.A., Marcucci, G., Heerema, N.A. & Byrd, J.C. (2013) Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. Leukaemia & Lymphoma, 54, 2654-2659.
60. Lanham, S., Hamblin, T., Oscier, D., Ibbotson, R., Stevenson, F. & Packham, G. (2003) Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood, 101, 1087-1093.
61. Lee, H.J., Gallardo, M., Zhang, X., Quintas-Cardama, A. & Post, S.M. (2013) p53 Pathway alterations influence survival and treatment response in chronic lymphocytic leukemia. Blood, 122, 2885.
62. Leporrier, M., Chevret, S., Cazin, B., Boudjerra, N., Feugier, P., Desablens, B., Rapp, M.J., Jaubert, J., Autrand, C., Divine, M., Dreyfus, B., Maloum, K., Travade, P., Dighiero, G., Binet, J.L. & Chastang, C. (2001) Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood, 98, 2319-2325.
63. Li, P.P. & Wang, X. (2013) Role of signaling pathways and miRNAs in chronic lymphocytic leukemia. Chinese Medical Journal, 126, 4175-4182.
64. Lin, T.S., Grever, M.R. & Byrd, J.C. (2005) Changing the way we think about chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 4009-4012.
65. Lin, T.S., Ruppert, A.S., Johnson, A.J., Fischer, B., Heerema, N.A., Andritsos, L.A., Blum, K.A., Flynn, J.M., Jones, J.A., Hu, W.H., Moran, M.E., Mitchell, S.M., Smith, L.L., Wagner, A.J., Raymond, C.A., Schaaf, L.J., Phelps, M.A., Villalona-Calero, M.A., Grever, M.R. & Byrd, J.C. (2009) Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. Journal of Clinical Oncology, 27, 6012-6018.
66. Liu, J., Zhang, C., Hu, W. & Feng, Z. (2013) Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Letters, doi 10.1016/j.canlet.2013.12.025.
67. Liu, J., Chen, G., Feng, L., Zhang, W., Pelicano, H., Wang, F., Ogasawara, M.A., Lu, W., Amin, H.M., Croce, C.M., Keating, M.J. & Huang, P. (2014) Loss of p53 and altered miR15-a/16-1short right arrowMCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells. Leukemia, 28, 118-128.
68. Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A.K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., Mahmoudi, A., Cathers, B., Rychak, E., Gaidarova, S., Chen, R., Schafer, P.H., Handa, H., Daniel, T.O., Evans, J.F. & Chopra, R. (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia, 26, 2326-2335.
69. Malcikova, J., Stalika, E., Davis, Z., Plevova, K., Trbusek, M., Mansouri, L., Scarfo, L., Baliakas, P., Gardiner, A., Sutton, L.A., Francova, H.S., Agathangelidis, A., Anagnostopoulos, A., Tracy, I., Makris, A., Smardova, J., Ghia, P., Belessi, C., Gonzalez, D., Rosenquist, R., Oscier, D., Pospisilova, S. & Stamatopoulos, K. (2014) The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors. British Journal of Haematology, doi 10.1111/bjh.12893.
70. Massion, P.P., Taflan, P.M., Jamshedur Rahman, S.M., Yildiz, P., Shyr, Y., Edgerton, M.E., Westfall, M.D., Roberts, J.R., Pietenpol, J.A., Carbone, D.P. & Gonzalez, A.L. (2003) Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Research, 63, 7113-7121.
71. Mauro, F.R., Molica, S., Laurenti, L., Cortelezzi, A., Carella, A.M., Zaja, F., Chiarenza, A., Angrilli, F., Nobile, F., Marasca, R., Musolino, C., Brugiatelli, M., Piciocchi, A., Vignetti, M., Fazi, P., Gentile, G., De Propris, M.S., Della Starza, I., Marinelli, M., Chiaretti, S., Del Giudice, I., Nanni, M., Albano, F., Cuneo, A., Guarini, A. & Foa, R. (2014) Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. Leukemia Research, 38, 198-203.
72. Molica, S. (2006) Sex differences in incidence and outcome of chronic lymphocytic leukemia patients. Leukaemia & Lymphoma, 47, 1477-1480.
73. Morschhauser, F., Cartron, G., Lamy, T., Milpied, N.J., Thieblemont, C., Tilly, H., Weisser, M., Birkett, J. & Salles, G.A. (2009) Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Blood, 114, 364.
74. Muller, P.A. & Vousden, K.H. (2014) Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell, 25, 304-317.
75. Neilson, J.R., Auer, R., White, D., Bienz, N., Waters, J.J., Whittaker, J.A., Milligan, D.W. & Fegan, C.D. (1997) Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia, 11, 1929-1932.
76. O'Brien, S., Lamanna, N., Kipps, T.J., Flinn, I., Zelenetz, A., Burger, J.A., Holes, L., Johnson, D.M., Gu, J., Dansey, R.D., Dubowy, R.L. & Coutre, S.E. (2013) A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Journal of Clinical Oncology (ASCO Annual Meeting Abstracts), 31, Abstract 7005.
77. Oren, M. & Rotter, V. (2010) Mutant p53 gain-of-function in cancer. Cold Spring Harbor Perspectives in Biology, 2, a001107.
78. Osada, M., Ohba, M., Kawahara, C., Ishioka, C., Kanamaru, R., Katoh, I., Ikawa, Y., Nimura, Y., Nakagawara, A., Obinata, M. & Ikawa, S. (1998) Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nature Medicine, 4, 839-843.
79. Parikh, S.A., Rabe, K.G., Smoley, S.A., Wiktor, A.E., Hanson, C.A., Shanafelt, T.D. & Van Dyke, D.L. (2013) Clonal evolution in patients with previously untreated chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts), 122, 1643.
80. Pettitt, A.R., Clarke, A.R., Cawley, J.C. & Griffiths, S.D. (1999) Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms. British Journal of Haematology, 105, 986-988.
81. Pettitt, A.R., Jackson, R., Carruthers, S., Dodd, J., Dodd, S., Oates, M., Johnson, G.G., Schuh, A., Matutes, E., Dearden, C.E., Catovsky, D., Radford, J.A., Bloor, A., Follows, G.A., Devereux, S., Kruger, A., Blundell, J., Agrawal, S., Allsup, D., Proctor, S., Heartin, E., Oscier, D., Hamblin, T.J., Rawstron, A. & Hillmen, P. (2012) Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the National Cancer Research Institute CLL206 trial. Journal of Clinical Oncology, 30, 1647-1655.
82. Phelps, M.A., Lin, T.S., Johnson, A.J., Hurh, E., Rozewski, D.M., Farley, K.L., Wu, D., Blum, K.A., Fischer, B., Mitchell, S.M., Moran, M.E., Brooker-McEldowney, M., Heerema, N.A., Jarjoura, D., Schaaf, L.J., Byrd, J.C., Grever, M.R. & Dalton, J.T. (2009) Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood, 113, 2637-2645.
83. Pileckyte, R., Jurgutis, M., Valceckiene, V., Stoskus, M., Gineikiene, E., Sejoniene, J., Degulys, A., Zvirblis, T. & Griskevicius, L. (2011) Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leukaemia & Lymphoma, 52, 1055-1065.
84. Rai, K.R., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G.A., Larson, R.A., Cheson, B.D. & Schiffer, C.A. (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. New England Journal of Medicine, 343, 1750-1757.
85. Ramsay, A.G., Johnson, A.J., Lee, A.M., Gorgun, G., Le Dieu, R., Blum, W., Byrd, J.C. & Gribben, J.G. (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. The Journal of Clinical Investigation, 118, 2427-2437.
86. Ramsay, A.G., Evans, R., Kiaii, S., Svensson, L., Hogg, N. & Gribben, J.G. (2013) Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood, 121, 2704-2714.
87. Raveche, E.S., Salerno, E., Scaglione, B.J., Manohar, V., Abbasi, F., Lin, Y.C., Fredrickson, T., Landgraf, P., Ramachandra, S., Huppi, K., Toro, J.R., Zenger, V.E., Metcalf, R.A. & Marti, G.E. (2007) Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood, 109, 5079-5086.
88. Ringshausen, I., Schneller, F., Bogner, C., Hipp, S., Duyster, J., Peschel, C. & Decker, T. (2002) Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood, 100, 3741-3748.
89. Robak, T., Jamroziak, K., Gora-Tybor, J., Stella-Holowiecka, B., Konopka, L., Ceglarek, B., Warzocha, K., Seferynska, I., Piszcz, J., Calbecka, M., Kostyra, A., Dwilewicz-Trojaczek, J., Dmoszynska, A., Zawilska, K., Hellmann, A., Zdunczyk, A., Potoczek, S., Piotrowska, M., Lewandowski, K. & Blonski, J.Z. (2010) Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the polish adult leukemia group (PALG-CLL3 study). Journal of Clinical Oncology, 28, 1863-1869.
90. Roberts, A.W., Seymour, J.F., Brown, J.R., Wierda, W.G., Kipps, T.J., Khaw, S.L., Carney, D.A., He, S.Z., Huang, D.C., Xiong, H., Cui, Y., Busman, T.A., McKeegan, E.M., Krivoshik, A.P., Enschede, S.H. & Humerickhouse, R. (2012) Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. Journal of Clinical Oncology, 30, 488-496.
91. Rossi, D., Cerri, M., Deambrogi, C., Sozzi, E., Cresta, S., Rasi, S., De Paoli, L., Spina, V., Gattei, V., Capello, D., Forconi, F., Lauria, F. & Gaidano, G. (2009) The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clinical Cancer Research, 15, 995-1004.
92. Rossi, D., Khiabanian, H., Spina, V., Ciardullo, C., Bruscaggin, A., Fama, R., Rasi, S., Monti, S., Deambrogi, C., De Paoli, L., Wang, J., Gattei, V., Guarini, A., Foa, R., Rabadan, R. & Gaidano, G. (2014) Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood, 123, 2139-2147.
93. Roue, G., Lopez-Guerra, M., Milpied, P., Perez-Galan, P., Villamor, N., Montserrat, E., Campo, E. & Colomer, D. (2008) Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clinical Cancer Research, 14, 6907-6915.
94. Salles, G.A., Karlin, L., Rule, S., Shah, N., Morschhauser, F., Terriou, L., Dyer, M.J.S., Hutchinson, C., Fegan, C., Cartron, G., Knurowski, T., Saunders, A.J., Wright, J.G., Honda, H., Mazur, A., Yoshizawa, T., Kawabata, K. & Birkett, J.T.P. (2013) A phase I study of the oral Btk inhibitor ONO-4059 in patients with relapsed/refractory and high risk chronic lymphocytic leukaemia (CLL). Blood (ASH Annual Meeting Abstracts), 122, 676.
95. Schmale, H. & Bamberger, C. (1997) A novel protein with strong homology to the tumor suppressor p53. Oncogene, 15, 1363-1367.
96. Scott, D.W., Mungall, K.L., Ben-Neriah, S., Rogic, S., Morin, R.D., Slack, G.W., Tan, K.L., Chan, F.C., Lim, R.S., Connors, J.M., Marra, M.A., Mungall, A.J., Steidl, C. & Gascoyne, R.D. (2012) TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. Blood, 119, 4949-4952.
97. Seymour, J.F., Davids, M.S., Pagel, J.M., Kahl, B.S., Wierda, W.G., Miller, T.P., Gerecitano, J.F., Kipps, T.J., Anderson, M.A., Huang, D.C.S., Rudersdorf, N.K., Gressick, L.A., Montalvo, N.P., Yang, J., Busman, T.A., Dunbar, M., Cerri, E., Enschede, S.H., Humerickhouse, R.A. & Roberts, A.W. (2013) Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Blood (ASH Annual Meeting Abstracts), 122, 872.
98. Shalom-Feuerstein, R., Lena, A.M., Zhou, H., Divonne, S.D., Van Bokhoven, H., Candi, E., Melino, G. & Aberdam, D. (2011) Delta Np63 is an ectodermal gatekeeper of epidermal morphogenesis. Cell Death and Differentiation, 18, 887-896.
99. Silber, R., Degar, B., Costin, D., Newcomb, E.W., Mani, M., Rosenberg, C.R., Morse, L., Drygas, J.C., Canellakis, Z.N. & Potmesil, M. (1994) Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood, 84, 3440-3446.
100. Stephens, D.M., Ruppert, A.S., Maddocks, K., Andritsos, L., Baiocchi, R., Jones, J., Johnson, A.J., Smith, L.L., Zhao, Y., Ling, Y.H., Li, J.A., Phelps, M.A., Grever, M.R., Byrd, J.C. & Flynn, J.M. (2013) Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leukemia Research, 37, 1195-1199.
101. Stephens, D.M., Ruppert, A.S., Jones, J.A., Woyach, J., Maddocks, K., Jaglowski, S.M., Andritsos, L.A., Flynn, J.M., Grever, M.R., Lozanski, G., Johnson, A.J., Muthusamy, N., Heerema, N.A. & Byrd, J.C. (2014) Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. Leukemia, 28, 1365-1368.
102. Stilgenbauer, S., Zenz, T., Winkler, D., Buhler, A., Schlenk, R.F., Groner, S., Busch, R., Hensel, M., Duhrsen, U., Finke, J., Dreger, P., Jager, U., Lengfelder, E., Hohloch, K., Soling, U., Schlag, R., Kneba, M., Hallek, M. & Dohner, H. (2009) Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology, 27, 3994-4001.
103. Strati, P., Keating, M.J., Wierda, W.G., Badoux, X.C., Calin, S., Reuben, J.M., O'Brien, S., Kornblau, S.M., Kantarjian, H.M., Gao, H. & Ferrajoli, A. (2013) Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood, 122, 734-737.
104. Tam, C.S., Shanafelt, T.D., Wierda, W.G., Abruzzo, L.V., Van Dyke, D.L., O'Brien, S., Ferrajoli, A., Lerner, S.A., Lynn, A., Kay, N.E. & Keating, M.J. (2009) De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D Anderson and Mayo Clinic experience.. Blood, 114, 957-964.
105. Thornton, P.D., Matutes, E., Bosanquet, A.G., Lakhani, A.K., Grech, H., Ropner, J.E., Joshi, R., Mackie, P.H., Douglas, I.D.C., Bowcock, S.J. & Catovsky, D. (2003) High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Annals of Hematology, 82, 759-765.
106. Trbusek, M., Smardova, J., Malcikova, J., Sebejova, L., Dobes, P., Svitakova, M., Vranova, V., Mraz, M., Francova, H.S., Doubek, M., Brychtova, Y., Kuglik, P., Pospisilova, S. & Mayer, J. (2011) Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. Journal of Clinical Oncology, 29, 2703-2708.
107. Trink, B., Okami, K., Wu, L., Sriuranpong, V., Jen, J. & Sidransky, D. (1998) A new human p53 homologue. Nature Medicine, 4, 747-748.
108. Vasmatzis, G., Johnson, S.H., Knudson, R.A., Ketterling, R.P., Braggio, E., Fonseca, R., Viswanatha, D.S., Law, M.E., Kip, N.S., Ozsan, N., Grebe, S.K., Frederick, L.A., Eckloff, B.W., Thompson, E.A., Kadin, M.E., Milosevic, D., Porcher, J.C., Asmann, Y.W., Smith, D.I., Kovtun, I.V., Ansell, S.M., Dogan, A. & Feldman, A.L. (2012) Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood, 120, 2280-2289.
109. Villunger, A., Michalak, E.M., Coultas, L., Mullauer, F., Bock, G., Ausserlechner, M.J., Adams, J.M. & Strasser, A. (2003) p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science, 302, 1036-1038.
110. Weber, A., Bellmann, U., Bootz, F., Wittekind, C. & Tannapfel, A. (2002) Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck. International Journal of Cancer, 99, 22-28.
111. Wierda, W.G., Kipps, T.J., Mayer, J., Stilgenbauer, S., Williams, C.D., Hellmann, A., Robak, T., Furman, R.R., Hillmen, P., Trneny, M., Dyer, M.J., Padmanabhan, S., Piotrowska, M., Kozak, T., Chan, G., Davis, R., Losic, N., Wilms, J., Russell, C.A. & Osterborg, A. (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 28, 1749-1755.
112. Wierda, W.G., Kipps, T.J., Durig, J., Griskevicius, L., Stilgenbauer, S., Mayer, J., Smolej, L., Hess, G., Griniute, R., Hernandez-Ilizaliturri, F.J., Padmanabhan, S., Gorczyca, M., Chang, C.N., Chan, G., Gupta, I., Nielsen, T.G. & Russell, C.A. (2011) Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood, 117, 6450-6458.
113. Woyach, J.A., Lozanski, G., Ruppert, A.S., Lozanski, A., Blum, K.A., Jones, J.A., Flynn, J.M., Johnson, A.J., Grever, M.R., Heerema, N.A. & Byrd, J.C. (2012) Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features. Leukemia, 26, 1442-1444.
114. Wu, L., Adams, M., Schafer, P., Muller, G., Stirling, D. & Bartlett, J.B. (2007) Lenalidomide strongly enhances natural killer cell and monocyte mediated antibody-dependent cellular cytotoxicity of rituximab treated CD20 + VE cancer cells in vitro. Haematologica - The Hematology Journal, 92, 113.
115. Wu, L., Adams, M., Carter, T., Chen, R., Muller, G., Stirling, D., Schafer, P. & Bartlett, J.B. (2008) Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20(+) tumor cells. Clinical Cancer Research, 14, 4650-4657.
116. Xu, W., Miao, K.R., Hong, M., Zhu, D.X., Fang, C., Dong, H.J., Wang, D.M., Cao, X. & Li, J.Y. (2010) High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia. European Journal of Cancer, 46, 2145-2149.
117. Yang, A.N., Kaghad, M., Wang, Y.M., Gillett, E., Fleming, M.D., Dotsch, V., Andrews, N.C., Caput, D. & McKeon, F. (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Molecular Cell, 2, 305-316.
118. Zenz, T., Krober, A., Scherer, K., Habe, S., Buhler, A., Benner, A., Denzel, T., Winkler, D., Edelmann, J., Schwanen, C., Dohner, H. & Stilgenbauer, S. (2008) Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood, 112, 3322-3329.
119. Zenz, T., Habe, S., Denzel, T., Mohr, J., Winkler, D., Buhler, A., Sarno, A., Groner, S., Mertens, D., Busch, R., Hallek, M., Dohner, H. & Stilgenbauer, S. (2009a) Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood, 114, 2589-2597.
120. Zenz, T., Mohr, J., Eldering, E., Kater, A.P., Buhler, A., Kienle, D., Winkler, D., Durig, J., van Oers, M.H., Mertens, D., Dohner, H. & Stilgenbauer, S. (2009b) miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood, 113, 3801-3808.
121. Zenz, T., Eichhorst, B., Busch, R., Denzel, T., Habe, S., Winkler, D., Buhler, A., Edelmann, J., Bergmann, M., Hopfinger, G., Hensel, M., Hallek, M., Dohner, H. & Stilgenbauer, S. (2010a) TP53 mutation and survival in chronic lymphocytic leukemia. Journal of Clinical Oncology, 28, 4473-4479.
122. Zenz, T., Vollmer, D., Trbusek, M., Smardova, J., Benner, A., Soussi, T., Helfrich, H., Heuberger, M., Hoth, P., Fuge, M., Denzel, T., Habe, S., Malcikova, J., Kuglik, P., Truong, S., Patten, N., Wu, L., Oscier, D., Ibbotson, R., Gardiner, A., Tracy, I., Lin, K., Pettitt, A., Pospisilova, S., Mayer, J., Hallek, M., Dohner, H. & Stilgenbauer, S. (2010b) TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia, 24, 2072-2079.